Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2009 1
2012 1
2013 1
2014 1
2015 2
2016 4
2017 4
2018 1
2019 3
2020 6
2021 4
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
ACROBAT Edge: Safety and Efficacy of Switching Injected SRLs to Oral Paltusotine in Patients With Acromegaly.
Gadelha MR, Gordon MB, Doknic M, Mezősi E, Tóth M, Randeva H, Marmon T, Jochelson T, Luo R, Monahan M, Madan A, Ferrara-Cook C, Struthers RS, Krasner A. Gadelha MR, et al. Among authors: gordon mb. J Clin Endocrinol Metab. 2023 Apr 13;108(5):e148-e159. doi: 10.1210/clinem/dgac643. J Clin Endocrinol Metab. 2023. PMID: 36353760 Free PMC article. Clinical Trial.
Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study.
Pivonello R, Bancos I, Feelders RA, Kargi AY, Kerr JM, Gordon MB, Mariash CN, Terzolo M, Ellison N, Moraitis AG. Pivonello R, et al. Among authors: gordon mb. Front Endocrinol (Lausanne). 2022 Apr 27;13:899616. doi: 10.3389/fendo.2022.899616. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35574017 Free PMC article.
Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide.
Samson SL, Nachtigall LB, Fleseriu M, Gordon MB, Bolanowski M, Labadzhyan A, Ur E, Molitch M, Ludlam WH, Patou G, Haviv A, Biermasz N, Giustina A, Trainer PJ, Strasburger CJ, Kennedy L, Melmed S. Samson SL, et al. Among authors: gordon mb. J Clin Endocrinol Metab. 2020 Oct 1;105(10):e3785-97. doi: 10.1210/clinem/dgaa526. J Clin Endocrinol Metab. 2020. PMID: 32882036 Free PMC article. Clinical Trial.
Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands.
Fleseriu M, Molitch M, Dreval A, Biermasz NR, Gordon MB, Crosby RD, Ludlam WH, Haviv A, Gilgun-Sherki Y, Mathias SD. Fleseriu M, et al. Among authors: gordon mb. Front Endocrinol (Lausanne). 2021 Mar 15;12:627711. doi: 10.3389/fendo.2021.627711. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33790860 Free PMC article. Clinical Trial.
Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial.
Fleseriu M, Dreval A, Bondar I, Vagapova G, Macut D, Pokramovich YG, Molitch ME, Leonova N, Raverot G, Grineva E, Poteshkin YE, Gilgun-Sherki Y, Ludlam WH, Patou G, Haviv A, Gordon MB, Biermasz NR, Melmed S, Strasburger CJ. Fleseriu M, et al. Among authors: gordon mb. Lancet Diabetes Endocrinol. 2022 Feb;10(2):102-111. doi: 10.1016/S2213-8587(21)00296-5. Epub 2021 Dec 22. Lancet Diabetes Endocrinol. 2022. PMID: 34953531 Clinical Trial.
32 results